Cargando…

Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study

BACKGROUND: The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and assess the prognostic value of specific immune biomarkers. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarradin, Victor, Lusque, Amélie, Filleron, Thomas, Dalenc, Florence, Franchet, Camille
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157437/
https://www.ncbi.nlm.nih.gov/pubmed/34039396
http://dx.doi.org/10.1186/s13058-021-01437-4
_version_ 1783699683491708928
author Sarradin, Victor
Lusque, Amélie
Filleron, Thomas
Dalenc, Florence
Franchet, Camille
author_facet Sarradin, Victor
Lusque, Amélie
Filleron, Thomas
Dalenc, Florence
Franchet, Camille
author_sort Sarradin, Victor
collection PubMed
description BACKGROUND: The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and assess the prognostic value of specific immune biomarkers. METHODS: Tumor-infiltrating lymphocytes (TILs) were identified from hematoxylin-eosin-stained sections of paired pre- and post-NACT tumor samples from a TNBC cohort (n = 66) and expression of PD-L1, TIM-3, and LAG-3 evaluated by immunohistochemistry. RESULTS: Overall TIL counts and PD-L1 expression did not differ pre- and post-NACT, but there was a response-specific statistically significant difference. TIL counts decreased in 65.5% of patients who achieved a pathological complete response (pCR) and increased in 56.8% of no-pCR patients (p = 0.0092). PD-L1 expression was significantly more frequently lost after NACT in pCR than in no-pCR patients (41.4% vs 16.2%, p = 0.0020). TIM-3 positivity (≥ 1%) was significantly more frequent after NACT (p < 0.0001) with increases in expression levels occurring more frequently in no-pCR than in pCR patients (51.4% vs 31%). LAG-3 expression significantly decreased after NACT, but there was no difference between response groups. Before NACT, a high TIL count (> 10%) was significantly associated with better overall survival (OS), p = 0.0112. After NACT, PD-L1 positivity and strong TIM-3 positivity (≥ 5%) were both associated with significantly worse OS (p = 0.0055 and p = 0.0274, respectively). Patients positive for both PD-L1 and TIM-3 had the worst prognosis (p = 0.0020), even when only considering patients who failed to achieve a pCR, p = 0.0479. CONCLUSIONS: NACT induces significant IME changes in TNBCs. PD-L1 and TIM-3 expression post-NACT may yield important prognostic information for TNBC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-021-01437-4.
format Online
Article
Text
id pubmed-8157437
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81574372021-05-28 Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study Sarradin, Victor Lusque, Amélie Filleron, Thomas Dalenc, Florence Franchet, Camille Breast Cancer Res Research Article BACKGROUND: The immune microenvironment (IME) of triple-negative breast cancers (TNBCs) and its modulation by neoadjuvant chemotherapy (NACT) remain to be fully characterized. Our current study aims to evaluate NACT-induced IME changes and assess the prognostic value of specific immune biomarkers. METHODS: Tumor-infiltrating lymphocytes (TILs) were identified from hematoxylin-eosin-stained sections of paired pre- and post-NACT tumor samples from a TNBC cohort (n = 66) and expression of PD-L1, TIM-3, and LAG-3 evaluated by immunohistochemistry. RESULTS: Overall TIL counts and PD-L1 expression did not differ pre- and post-NACT, but there was a response-specific statistically significant difference. TIL counts decreased in 65.5% of patients who achieved a pathological complete response (pCR) and increased in 56.8% of no-pCR patients (p = 0.0092). PD-L1 expression was significantly more frequently lost after NACT in pCR than in no-pCR patients (41.4% vs 16.2%, p = 0.0020). TIM-3 positivity (≥ 1%) was significantly more frequent after NACT (p < 0.0001) with increases in expression levels occurring more frequently in no-pCR than in pCR patients (51.4% vs 31%). LAG-3 expression significantly decreased after NACT, but there was no difference between response groups. Before NACT, a high TIL count (> 10%) was significantly associated with better overall survival (OS), p = 0.0112. After NACT, PD-L1 positivity and strong TIM-3 positivity (≥ 5%) were both associated with significantly worse OS (p = 0.0055 and p = 0.0274, respectively). Patients positive for both PD-L1 and TIM-3 had the worst prognosis (p = 0.0020), even when only considering patients who failed to achieve a pCR, p = 0.0479. CONCLUSIONS: NACT induces significant IME changes in TNBCs. PD-L1 and TIM-3 expression post-NACT may yield important prognostic information for TNBC patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13058-021-01437-4. BioMed Central 2021-05-26 2021 /pmc/articles/PMC8157437/ /pubmed/34039396 http://dx.doi.org/10.1186/s13058-021-01437-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Sarradin, Victor
Lusque, Amélie
Filleron, Thomas
Dalenc, Florence
Franchet, Camille
Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title_full Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title_fullStr Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title_full_unstemmed Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title_short Immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the MIMOSA-1 study
title_sort immune microenvironment changes induced by neoadjuvant chemotherapy in triple-negative breast cancers: the mimosa-1 study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8157437/
https://www.ncbi.nlm.nih.gov/pubmed/34039396
http://dx.doi.org/10.1186/s13058-021-01437-4
work_keys_str_mv AT sarradinvictor immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study
AT lusqueamelie immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study
AT filleronthomas immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study
AT dalencflorence immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study
AT franchetcamille immunemicroenvironmentchangesinducedbyneoadjuvantchemotherapyintriplenegativebreastcancersthemimosa1study